2

Led by Prof. Liu Mingyao from the School of Life Sciences, the ECNU team published a research article titled "Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL" in Nature. The team successfully developed a two-in-one approach to generate non-viral, gene-specific targeted CAR-T cells through CRISPR–Cas9. This is the best clinical result so far in the global CAR-T cell therapy for refractory and relapsed lymphoma with high remission rate and low toxicity, marking that Chinese scientists are in an internationally leading position in the field of CAR-T cell research, development, and clinical translation.